United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024.

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...

Check Out Our Latest Analysis on United Therapeutics United Therapeutics Stock Down 1.6 % UTHR stock opened at $313.60 on Wednesday. United Therapeutics has a 52-week low of $221.53 and a 52-week ...

United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The business’s fifty day moving average price is $349.12 and its 200 day moving average price is $358.27.

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported fourth-quarter net income of $301.3 million. The Silver Spring, Maryland-based ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares. United Therapeutics’ Q4 earnings ...

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations ...

In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on United Therapeutics (UTHR – Research Report), with a price target of $395.00. The company’s shares ...